Research programme: diabetes/obesity therapy - CytRx

Drug Profile

Research programme: diabetes/obesity therapy - CytRx

Alternative Names: Obesity therapy research programme - CytRx; Rip140

Latest Information Update: 05 Dec 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Imperial Innovations
  • Developer CytRx Corporation
  • Class Small interfering RNA
  • Mechanism of Action Genetic transcription inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity; Type 2 diabetes mellitus

Most Recent Events

  • 05 Dec 2008 Discontinued - Preclinical for Obesity in USA (unspecified route)
  • 05 Dec 2008 Discontinued - Preclinical for Type-2 diabetes mellitus in USA (unspecified route)
  • 31 Aug 2005 A preclinical study has been added to the Obesity pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top